HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced that a peer-reviewed article published in JACC: Advances demonstrated that a risk prediction algorithm incorporating its credit card-sized ECG device can accurately identify heart attack risk in patients presenting with chest pain. The proof-of-concept study, which evaluated 184 patients, found that the algorithm achieved an area under the curve (AUC) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms. When a personal, symptom-free baseline ECG was available for comparison, the AUC rose to 92.9%. The company stated that these results support heart attack detection as a future indication for the HeartBeam System and advance its broader clinical program.
This development is significant for business leaders and healthcare professionals as it highlights the potential for portable, cost-effective cardiac monitoring outside traditional clinical settings. The HeartBeam device is designed to be cable-free and capable of collecting ECG signals in 3D from three non-coplanar directions, synthesizing them into a 12-lead ECG. This platform technology aims to deliver actionable heart intelligence wherever the patient is, potentially reducing hospital burden and enabling earlier intervention. For leaders in the technology and healthcare sectors, this study signals a shift toward decentralized cardiac care, where physicians can identify trends and acute conditions remotely, directing patients to appropriate care without requiring a hospital visit.
The implications for the industry are substantial. As remote patient monitoring gains traction, devices like HeartBeam could reduce emergency department overcrowding by allowing low-risk patients to be triaged at home. The study’s high AUC values suggest that the algorithm could be integrated into clinical workflows to improve diagnostic accuracy for acute coronary syndrome. For investors, this news reinforces the commercial viability of HeartBeam’s technology, which already received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company holds over 20 issued patents related to its technology enablement, as detailed on its Indications for Use page.
For further information, the full press release is available at https://ibn.fm/ainxV. Interested parties can also find updates on HeartBeam in the company’s newsroom at https://ibn.fm/BEAT. As with all forward-looking statements, the company notes risks and uncertainties that could affect actual results, as outlined in its filings with the SEC.
